Yu.V. Gorinova

Yu.V. Gorinova

Auto-generated profile, based on publicly available information

Yu.V. Gorinova

Federal State Autonomous Institution “National Medical Research Center for Children’s Health” of the Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2019 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
NPNika V. Petrova
Nika V. Petrova
NKNataliya Kashirskaya
Nataliya Kashirskaya
DSD. K. Saydaeva
D. K. Saydaeva
Aleksander V. PolyakovAleksander V. Polyakov
Aleksander V. Polyakov
TAT.A. Adyan
T.A. Adyan
RZRena A Zinchenko
Rena A Zinchenko
Cystic fibrosis (CF; OMIM #219700) is a common autosomal recessive disease caused by pathogenic variants (henceforward mutations) in the cystic fibrosis transmembrane conductance regulator gene (CFTR). The spectrum and frequencies of CFTR mutations vary among different populations. Characterization of the specific distribution of CFTR mutations can be used to optimize genetic counseling, foster reproductive choices, and facilitate the introduction of mutation-specific therapies. Chechens are a distinct Caucasian ethnic group of the Nakh peoples that originated from the North Caucasus. Chechens are one of the oldest ethnic groups in the Caucasus, the sixth largest ethnic group in the Russian Federation (RF), and constitute the majority population of the Chechen Republic (Chechnya). The spectrum of CFTR mutations in a representative cohort of Chechen CF patients and healthy individuals was analyzed. Molecular genetic analysis of 34 CFTR mutations (representing approx. 80–85% of mutations in multiethnic CF populations of the RF) was performed in 32 CF patients from 31 unrelated Chechen families living in Chechnya. One hundred randomly chosen healthy Chechens were analyzed for the 15 most common “Russian” mutations. The clinical symptoms in Chechen CF patients with different CFTR genotypes were investigated. High frequencies of c.1545_1546delTA (p.Tyr515X; 1677delTA) (52 out of 64 CFTR alleles tested; 81.3%) and c.274G > A (p.Glu92Lys, E92K) (8/64, 12.5%) mutations were found. Twenty patients were homozygous for the c.1545_1546delTA mutation, and eight were compound heterozygous for the c.1545_1546delTA and c.274G > A mutations. Three carriers of the c.1545_1546delTA mutation were also found in the cohort of 100 apparently healthy Chechens (frequency – 0.015). The c.1545_1546delTA and c.274G > A mutations are linked to the same haplotype (22–7–16–13) of intragenic Short Tandem Repeat markers, i.e., IVS1CA, IVS6aGATT, IVS8CA, and IVS17bCA. The distribution of CFTR mutations in the Chechen CF population is unique regarding the high frequency of mutations c.1545_1546delTA and c.274G > A (more than 90% of the mutant alleles). The c.274G > A mutation is associated with a less severe course of CF than that observed in c.1545_1546delTA homozygotes. Testing for these two variants can be proposed as the first step of CF DNA diagnosis in the Chechen population.

27 May 2022 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
ABAlexander A. Baranov
Alexander A. Baranov
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
SKSergei I. Kutsev
Sergei I. Kutsev
SASergey Avdeev
Sergey Avdeev
EPElena V. Polevichenko
Elena V. Polevichenko
ЭСЭ. В. Синьков
Э. В. Синьков
The problem of timely diagnosis and proper management of patients with cystic fibrosis is crucial not only in our country, but throughout the world. Experts of the Union of Pediatricians of Russia have considered various issues of etiology, pathogenesis, epidemiology, diagnosis, and treatment of this genetic disease in a modern light. Particular attention was paid to screening methods for early diagnosis of cystic fibrosis. The principles of complex therapy were justified, including rational use of antibacterial and mucolytic drugs and enzyme replacement therapy that significantly determine the disease prognosis.

26 October 2020 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
EKElena Kondatyeva
Elena Kondatyeva
СКС. А. Красовский
С. А. Красовский
NKNataliya Kashirskaya
Nataliya Kashirskaya
EAElena Amelina
Elena Amelina
EZElena Zhekaite
Elena Zhekaite
НКН. Ю. Каширская
Н. Ю. Каширская
Since the beginning of the COVID-19 epidemic, the European cystic fibrosis society (ECFS) has decided to launch a special ECFS-COVID-19 program to collect information on the of COVID-19 characteristics in the patients with cystic fibrosis (CF). The results of the program should help timely and efficiently provide the patients with CF with the necessary care. Initially, it was assumed that COVID-19 would be severe in CF patients. The aim. Тo assess the prevalence and characteristics of COVID-19 in patients with cystic fibrosis (CF) in the Russian Federation (RF). Methods. 6 cases (4 children and 2 adults) of COVID-19 in Russian CF patients were analyzed. Results. There are 405,843 infected with SARS-CoV-2 in Russia, the incidence of coronavirus infection in Russia was 1.4 cases per 1 thousand people. According to the Ministry of Health of the RF, as of December 2019, there were 3,931 patients with CF (2,823 children and 1,108 adults). The incidence of COVID-19 was 1.5 per 1000 patients with CF (1.4 : 1,000 for children and 1.8 : 1,000 for adults). The incidence was not higher than in the General population. The diagnosis of COVID-19 was confirmed in 4 boys and 2 women, 3 of the patients were infected with Pseudomonas aeruginosa and 2 – with Achromobacter spp. Mild disease was seen in 5 patients including all the children. Pneumonia was registered in 3 patients. One child with COVID-19 had abdominal syndrome. 2 patients – 1 adult and 1 child – needed in-patient care. Additional antibiotics were given to 4 patients, 2 of them received i/v antibiotics. One adult patient was on the lung transplantation waiting list. This woman had long-term oxygen therapy and BiPAP noninvasive respiratory support before the infection with SARS-CoV-2, FEV1 was 24 %pred. Conclusion. Despite the fact that patients with CF are at risk of severe COVID-19, to date, in the described cases, COVID-19 infection has not led to a significant deterioration of the symptoms of CF. Not a single fatal outcome in Russian patients with CF has been recorded.

24 June 2016 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
SKS. A. Krasovskiy
S. A. Krasovskiy
NKNataliya Kashirskaya
Nataliya Kashirskaya
ACA. V. Chernyak
A. V. Chernyak
EAElena Amelina
Elena Amelina
NPNika V. Petrova
Nika V. Petrova
DKD. V. Kadyrova
D. V. Kadyrova
Генетическому разнообразию больных муковисцидозом (МВ) в России посвящены единичные работы на ограниченной выборке больных. Цель. Выявление особенностей генетического профиля больных МВ в России по данным Национального регистра (2014). Материалы и методы. Данные пациентов с МВ (n = 2 131) из 74 регионов России, включенные в Национальный регистр больных МВ (2014). Результаты. Генетическое обследование проведено у 89,0 % больных, суммарная аллельная частота выявленных мутаций составила 81,2 %. Выявлено 122 мутации, которые сформировали 173 различных генотипа, среди которых доля «мягких» генотипов составила 23,0 %. Аллельная частота самых распространенных мутаций представлена в порядке убывания: F508del – 51,53 %, СFTRdele2,3 – 5,93 %, E92K – 2,62 %, 3849+10kbC>T – 2,14 %, 2184insA – 1,80 %, W1282X – 1,80 %, 2143delT – 1,69 %, N1303K – 1,43 %, G542X – 1,16 %, 1677delTA – 0,98 %, L138ins – 0,95 %, R334W – 0,85 %, 394delTT – 0,85 %, 3821delT – 0,42 %, 2789+5G>A – 0,37 %, S466X – 0,37 %, S1196X – 0,37 %, 3272-16T>A – 0,34 %, W1282R – 0,29 %, 3944delGT – 0,21 %. Выявлено, что особенностями распределения мутаций. CFTRсреди российских больных МВ являются меньшая частота доминирующих в мире мутаций, таких как F508del, G542X, N1303K, единичная встречаемость мутаций G551D, 1717-1G>A, 2183AA>G и наоборот – более высокая частота мутаций, являющихся относительно редкими в западноевропейских странах: СFTRdele2,3, E92K, 2184insA, 2143delT, 1677delTA, L138ins. Другой особенностью является более высокая встречаемость «мягких» мутаций в России по сравнению со странами Европы. Выявлено, что доля «мягких» мутаций в популяции больных МВ на протяжении последних лет увеличивается. Заключение. При формировании населения России особенности генетического профиля российских больных МВ определяются славянскими, тюркскими и финно-угорскими влияниями.

1 April 2018 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
YGYulia Gorinova
Yulia Gorinova
KSKirill Savostyanov
Kirill Savostyanov
APAleksander Pushkov
Aleksander Pushkov
ANAlexey Nikitin
Alexey Nikitin
EPEvgeniy Pen’kov
Evgeniy Pen’kov
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
ГЕНОТИП-ФЕНОТИПИЧЕСКИЕ КОРРЕЛЯЦИИ ТЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА У РОССИЙСКИХ ДЕТЕЙ. ПЕРВОЕ ОПИСАНИЕ ОДИННАДЦАТИ НОВЫХ МУТАЦИЙ

27 March 2020 in Russian Pediatric Journal
Verified
Journal Article
Open access
OSOlga I. Simonova
Olga I. Simonova
YGYulia V. Gorinova
Yulia V. Gorinova
VCVera P. Chernevich
Vera P. Chernevich
The review presents new data on the latest advances in the treatment of cystic fibrosis, a rare genetic disease. The methods used were literature search in the Scopus, Web of Science, and EMBASE databases. The importance of a number of drugs prescribed for anti-inflammatory purposes (ibuprofen, azithromycin) is discussed, data from multicenter studies of new drugs are presented. The role of mucolytic agents and the need to develop new antibacterial compounds are shown. Particular attention in the review is given to the development of new targeted therapies for cystic fibrosis. The data of studies of ivacaftor, lumacactor, tezacactor in this category of patients are presented, as well as a spectrum of mutations of the cystic fibrosis gene in which these molecules can be prescribed. The experience of the use of correctors in adult patients with cystic fibrosis in the Russian Federation is described, the effectiveness and safety of the long-term use of these drugs are described.